Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 260459

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Therapeutic
  • Gastrointestinal
  • Delivery
  • Disease
  • Osteoarthritis
  • Arthritis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 260459

License Grant
Licensor grants to the Licensee of Sweden an exclusive license, with the right to grant sublicenses, under the Licensed Technology to make, use, have made, sell, offer for sale, import, and export Products in the Field of Use in the Territory.

Licensor grants a license to use the Licensor House Marks in connection with the Commercialization of Licensor Products in the Field of Use in the Territory.

Licensor grants an option for a period of twenty-four months the Japan Option Period after the Effective Date to include Japan in the Territory to Licensee.

License Property
Licensors Product means any product that combines a Gastroprotective Agent and any NSAID in a single fixed combination dosage form, that would, if made, used, sold, offered for sale, had made, imported or exported without a license from Licensor of the Licensed Patents, infringe one or more Valid Claims of the Licensed Patents.

Esomeprazole means that certain pharmaceutical compound with the name (5-methoxy-2-{(S)-[ ( 4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl }-1 H-benzimidazole ), including any salts, hydrates, solvates, polymorphs and tautomers thereof.

Naproxen means that certain pharmaceutical compound with the chemical name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneaceti,c acid, including any esters, salts, hydrates, solvates and polymorphs thereof.

The patent is for Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs.

Field of Use
Field of Use means the treatment of human diseases and conditions by means of a pharmaceutical product.  These Pharmaceutical Compositions are for the Coordinated Delivery of NSAIDs.

IP relates to the sublicenses’s proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet.  Naproxen is used to relieve pain from various conditions such as headache, muscle aches, tendonitis, dental pain, and menstrual cramps. It also reduces pain, swelling, and joint stiffness caused by arthritis, bursitis, and gout attacks. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).

IPSCIO Record ID: 3520

License Grant
Licensee is acquiring all of the original Licensee's rights, title and interest in a separate agreement also dated November 18, 2013.  Licensee entered into agreements with the original Licensee where it acquired certain intellectual property and other assets, and certain liabilities, each with respect to VIMOVO.  It obtained rights to develop other pharmaceutical products that contain gastroprotective agents in a single fixed combination oral solid dosage form with NSAIDs in the United States.
License Property
VIMOVO (naproxen/esomeprazole magnesium) is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a proton pump inhibitor, or PPI, layer surrounding the core. VIMOVO was first developed by original Licensee together with Licensor and through an exclusive global collaboration and license agreement under which original Licensee and Licensor agreed to co-develop VIMOVO and original Licensee obtained exclusive rights to commercialize VIMOVO worldwide.

VIMOVO is an arthritis pain reliever that can also help avoid some stomach issues common to NSAIDs.

IPSCIO Record ID: 27649

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses under the licensed technology to make, use, have made, sell, offer for sale, import and export products.

Licensor grants a license to use the house marks in connection with the commercialization of the products.

License Property
The licensed technology is US patent 6926907 and filed patent serial no. 11/129,320, pharmaceutical compositions for the coordinated delivery of NSAIDs.

NSAID means any non-steroidal anti-inflammatory drug, the primary mechanism of action of which is inhibition of cyclooxygenase, but excluding acetyl salicylic acid.

Field of Use
The field of use is the treatment of human diseases and conditions by means of a pharmaceutical product.

IPSCIO Record ID: 280946

License Grant
Licensor agrees to grant and hereby grants to Licensee the following licenses, with the right to sublicense, under the Licensor Patents and Licensor Know-How (i) an exclusive (even as to Licensor) license in the Territory to develop, import, use, sell and offer for sale Licensed Products for Licensed Indications in the Field; and (ii) a non-exclusive worldwide license to develop, import, make and have made Licensed Products solely for sale in the Territory in the Field, which license shall be exclusive, even as to Licensor, regarding import and sale of Licensed Products in the Field in the Territory.
License Property
Licensor Patents means (i) the patents and patent applications listed, including those in-licensed by Licensor in the Missouri Agreement; and (ii) all additional patent applications and patents owned or Controlled by Licensor in the Territory which are directed to pharmaceutical products containing one or more PPIs with one or more buffering agents and which pharmaceutical products provide for immediate release of the PPI included in such product.
5,840,737 – Omeprazole solution and method for using same
6,489,346 – Substituted benzimidazole dosage forms and method of using same
6,780,882 – Substituted benzimidazole dosage forms and method of using same

Product(s) means pharmaceutical compositions containing any one or more PPIs in combination with one or more buffering agents, which pharmaceutical compositions provide for immediate release of the PPI included in such product, including (i) any prodrugs and metabolites, and all esters, salts, hydrates, solvates, polymorphs and isomers of any of the above, (ii) chemical analogs, and (iii) Formulations (including tablets, chewable tablets, capsules, caplets, liquid forms and powders for oral suspensions) of any of the above.

PPI means proton pump inhibitor.

Licensed Product(s) means any of the following OTC Products (i) Products containing a 20 mg dose of omeprazole and no other PPI, (ii) Products containing omeprazole (and no other PPI) at doses other than 20 mg, (iii) Combination Products that are approved.

OTC Product means all Formulations, dosages, package sizes and configurations and types of Products for which a prescription from a health care practitioner is not required in order to dispense, purchase or use such Product in the Territory.

The product is Zegerid® branded immediate-release omeprazole products for the over-the-counter (“OTC”).  Zegerid is a proton pump inhibitor (PPI), the strongest and most effective class of acid-reducing medication for treating frequent heartburn.

Field of Use
Field means all therapeutic uses and Indications in humans for which a physician’s prescription is not required. This may be used interchangeably with the phrase “OTC market”.
It can treat heartburn, a damaged esophagus, stomach ulcers, and gastroesophageal reflux disease (GERD).

IPSCIO Record ID: 266830

License Grant
This amendment expands the scope of the development plan, and updates the terms of consideration.

From the original agreement
Licensor grants to the Licensee of Sweden an exclusive license, with the right to grant sublicenses, under the Licensed Technology to make, use, have made, sell, offer for sale, import, and export Products in the Field of Use in the Territory.

Licensor grants a license to use the Licensor House Marks in connection with the Commercialization of Licensor Products in the Field of Use in the Territory.

Licensor grants an option for a period of twenty-four months the Japan Option Period after the Effective Date to include Japan in the Territory to Licensee.

The original agreement is exclusive.

License Property
The scope of the agreement is now expanded to PN400-1XX, PN400-1YY, PN400-3ZZ, and PN400-3AA Studies means the PN400-1XX, PN400-1 YY, PN400-3ZZ, and PN400-3AA Studies described in the U.S.
Development Plan, each of which may be referred to individually.
Field of Use
Under the PN program, Licensee has completed formulation development and clinical studies for several combinations of a PPI and an NSAID in a single tablet intended to provide effective management of pain and inflammation associated with chronic conditions such as osteoarthritis, and intended to have fewer gastrointestinal complications compared to an NSAID taken alone in patients at risk for developing NSAID associated gastric ulcers.

IPSCIO Record ID: 240601

License Grant
The Licensor of Denmark and Licensee are engaged in the development, production, and commercialization of pharmaceutical products and possess information and technology relating to the manufacture, use, and formulation of such products.

The Licensor of Denmark grants to an exclusive, even as to Licensor; in the Field in the Exclusive Territory to use the Licensor Product Deliverables and investigational new drug, or IND, Deliverables to make, have made under contract, use, develop and have developed under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances, in each case during the Option Period solely in connection with the Initial Development Program.

Licensor grants an exclusive option during the Option Period to license the Licensed Technology for the research, development and Commercialization of Licensee Products on the terms set forth in this Agreement.

Licensor grants an exclusive, even as to Licensor, with the right to grant sublicenses, under the Licensed Technology to develop, have developed under contract, use, offer to sell, sell, have sold, distribute and import pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances in the Exclusive Territory in the Field.

Licensor grants an exclusive, except as to Licensor or its licensees or sublicensees, license, with the right to grant sublicenses, under the Licensed Technology to develop, have developed under contract, use, offer to sell, sell, have sold, distribute and import pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances in the Limited Territory in the Field.

Licensor grants an exclusive, even as to Licensor, license, with the right to grant sublicenses, under the Licensed Technology to make and have made under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances for the Field in the Exclusive Territory.

Licensor grants a non-exclusive, license under the Licensed Technology, with the right to grant sublicenses, to make and have made under contract pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance and pharmaceutical products containing Lornoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more other active drug substances for the Field outside the Exclusive Territory.

For the Isomer Option, Licensor grants a right of first refusal on an exclusive license, with the right to grant sublicenses, under any applicable Patent, Know-How or intellectual property other than Patents, Controlled by Licensor relating to any Isomer Product to develop, have developed under contract, make, have made under contract, use, offer to sell, sell, have sold, distribute and import such Isomer Product in the Field in the Exclusive Territory.

License Property
Single Entity Product means a pharmaceutical product containing Lornoxicam, or any salts, solvates or polymorphs thereof, as the single active drug substance, and developed or manufactured by or on behalf of Licensee or Sublicensees using or referencing the Licensed Technology or any part thereof, or the use, manufacture or sale of which would, but for the licenses granted herein, infringe any Licensed Patents or intellectual property right other than Patents included in the Licensed Technology.

Combination Product means a pharmaceutical product containing Lomoxicam, or any salts, solvates or polymorphs thereof, as an active drug substance in combination with one or more additional active drug substances, and developed or manufactured by or on behalf of Licensee or Sublicensees using or referencing the Licensed Technology or any part thereof, or the use, manufacture or sale of which would, but for the licenses granted herein, infringe any Licensed Patents or intellectual property right other than Patents included in the Licensed Technology.

Isomer Product means a pharmaceutical product containing an isomer of Lornoxicam as either the single active drug substance or as an active drug substance in combination with one or more other active drug substances, developed solely by Licensor, and for which Licensor files an IND or equivalent filing in the Exclusive Territory within five years of the Effective Date.

Lornoxicam means the active drug substance known as lornoxicam, having the chemical structure set forth in this Agreement.

Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties.

Field of Use
Lornoxicam is a potent analgesic pain reliever, which makes it an attractive candidate for combination therapy.

IPSCIO Record ID: 4380

License Grant
The Australian Licensor grants to the Licensee a sole and exclusive, world-wide, royalty-bearing right and License under the IP to develop, make, have made, use, sell, offer to sell and import Licensed Products. The Licensor retains all other rights to the IP.
License Property
The Licensee may grant Sublicenses.

The Licensed Technology relates to methods and apparatus for producing APIs having an average particle size of 1,000 nanometers or less, including nano-milling methods and apparatus and pharmacoactive compositions of matter having an particle size of 1,000 nanometers or less and methods for their use.  

The reformulation efforts as to Indocin®/Indocid® and the Initial Selected Compounds shall be performed in accordance with the milestones specified.

Indocin is a nonsteroidal anti-inflammatory drug (NSAID).

Field of Use
NSAID is used to treat mild to moderate pain and help relieve symptoms of arthritis (e.g., osteoarthritis and rheumatoid arthritis) or gout, such as inflammation, swelling, stiffness, and joint pain.

IPSCIO Record ID: 282791

License Grant
The original agreement for commercialization of ConsensiTM in the U.S has been amended to include creating a near-term revenue streams to support further development of our oncology pipeline, engage a distribution partner with an established sales network and access to thousands of pharmacies to drive the launch of the drug.  In addition, a marketing plan and pricing strategy have been finalized.
License Property
Licensor is a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance.

ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

Field of Use
The Indications and Usage for Consensiâ„¢ is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions.

IPSCIO Record ID: 66786

License Grant
The company transferred to the Licensee, a Swedish corporation, the Investigational New Drug (IND) and New Drug Applications (NDA) for the product.  The Licensee is responsible for the commercialization of VIMOVO.  The Licensee will have rights to commercialize VIMOVO outside of the United States.
License Property
VIMOVO is the brand name for a proprietary fixed-dose combination of enteric-coated naproxen, a pain-relieving NSAID and immediate-release esomeprazole magnesium, a PPI, in a single delayed-release tablet and is a product in our PPI-NSAID (“PN”) platform.  It is for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers
Field of Use
This agreement pertains to the drug industry relating to the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.  Also to decrease the risk of gastric ulcers.

IPSCIO Record ID: 203448

License Grant
Licensor grants to the Licensee, of the Netherlands, an exclusive license, with the right to sublicense to its Affiliates, under the Licensors Technology to develop, have developed, import, make, have made, use; offer to sell, sell, commercialize and distribute the Licensed Product in the Field in the Territory for the purpose of Manufacturing, seeking Regulatory Approval for and/or Commercializing Licensed Products.
License Property
Marketing partnership is for Dyloject® (diclofenac sodium for injection).  Dyloject is an injectable formulation of diclofenac in Phase 3 clinical development in the United States and marketed in the United Kingdom. Diclofenac is a prescription nonsteroidal anti-inflammatory drug ('NSAID') that is widely prescribed to treat post-operative pain.  Dyloject provides an attractive alternative to other NSAIDs for the treatment of post-operative and acute pain to decrease the need for morphine or other opioids.

Compound means diclofenac sodium having the chemical name 2- [ (2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt.

The Licensed Product means any intramuscular or intravenous injectable form of a pharmaceutical product that contains the Licensed Formulation either alone or in combination with one or more other active ingredients. For the avoidance of doubt and unless otherwise mutually agreed by the Parties, each in its sole discretion, Licensed Product excludes oral, inhalable and other formulations and dosage forms that are not intramuscular or intravenous injectable formulations or dosage forms.

The patents include Pharmaceutical Composition, Stable Injectable Compositions, Formulations Of Low Dose Non- Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin, Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin, and, Methods Of Treating Pain While Minimizing Adverse Effects On Platelet Function.

Field of Use
The Field means the treatment, prevention, modulation or diagnosis of any disease, disorder or condition in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.